Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

[1]  S. Solomon,et al.  Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2004, European heart journal.

[2]  V. Strand,et al.  Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. , 2004, Rheumatology.

[3]  A. Bolger,et al.  Beta-blockers for chronic heart failure: surviving longer but feeling better? , 2003, International journal of cardiology.

[4]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[5]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[6]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[7]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[8]  M. Pfeffer,et al.  Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme , 2003, European journal of heart failure.

[9]  Vera Bittner,et al.  Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. , 2002, Heart & lung : the journal of critical care.

[10]  A. Dilenarda,et al.  [Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure]. , 2000, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[11]  M. Pfeffer,et al.  Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. , 2000, American heart journal.

[12]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[13]  A. di Lenarda.  [Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure]. , 2000, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[14]  D A Bloch,et al.  Capturing the patient's view of change as a clinical outcome measure. , 1999, JAMA.

[15]  Milton Packer,et al.  Safety and efficacy of carvedilol in severe heart failure , 1997 .

[16]  J. Cohn,et al.  Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. , 1997, Journal of cardiac failure.

[17]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.

[18]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[19]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[20]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.